GOG-3127: A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FR?-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FR?-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI

For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT07218809?term=trevi&viewType=Card&rank=2

Contact name

Laura Morse Cucci

Clinical trials study type

Oncology - Gynecologic

Clinical trials trial status

Open to Accrual

IRB number

2407503

Principal investigator

Fong Liu, MD

Clinical trials study number

G2512

Phone

443-849-3122

Fax

443-849-3777

Clinical trials title (full)

GOG-3127: A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRa-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRa-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)